default_top_notch
default_news_top
default_news_ad1
default_nd_ad1

Regulator to hold fifth review on suspected accounting breach by Samsung BioLogics

기사승인 2018.07.12  09:38:02

공유
default_news_ad2

The financial regulator is set to hold its fifth review session on a suspected accounting breach by Samsung BioLogics Co., officials said Thursday.

The Thursday session, which aims to decide punitive measures financial authorities could take against Samsung BioLogics over the alleged breach, is likely to pave the way for the Financial Services Commission (FSC) to make a final ruling by next Wednesday.

Samsung BioLogics' corporate logo (Yonhap)

If the FSC judges that the suspected breach was intentional, Samsung BioLogics would face tougher punishments, including a suspension in trading of its shares.

If the suspected breach is found to have been caused by negligence, however, the level of punishment would be less severe.

In May, financial authorities gave a preliminary notice to Samsung BioLogics that it broke accounting rules in 2015.

The regulatory review centers on questions about the biopharmaceutical company's sudden profits in 2015 after years of losses. Samsung BioLogics reported a net profit of 1.9 trillion won (US$1.72 billion) that year after changing the method used to calculate the value of its affiliate, Samsung Bioepis.

Samsung BioLogics has claimed that the change was in line with international accounting standards. (yonhap)

Hillary Kang edt@koreapost.com

<저작권자 © 코리아포스트 무단전재 및 재배포금지>
default_news_ad5
default_side_ad1
default_nd_ad2

인기기사

default_side_ad2

포토

1 2 3
set_P1
default_side_ad3

섹션별 인기기사 및 최근기사

default_side_ad4
default_nd_ad6
default_news_bottom
default_nd_ad4
default_bottom
#top
default_bottom_notch